Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

This study tests lisaftoclax (APG-2575), a drug that blocks a protein that helps cancer cells avoid dying, for people with relapsed or hard-to-treat leukemia and related blood cancers. It is testing the drug alone and in combination with other treatments. **You may be eligible if...** - You are 18 or older - You have been diagnosed with relapsed or refractory acute myeloid leukemia (AML), or a related blood cancer such as myelodysplastic syndrome (MDS), CMML, or mixed-phenotype leukemia - You have measurable disease and are in adequate overall health - You have received prior treatment that is no longer working **You may NOT be eligible if...** - You have active central nervous system (brain) involvement of your leukemia - You have uncontrolled infections - You have serious heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.